{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:19:28Z","timestamp":1776259168406,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Kaiser Permanente Northern California Graduate Medical Education (GME) program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1245\/s10434-025-19053-3","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T21:19:49Z","timestamp":1768339189000},"page":"4436-4442","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multigene Germline Testing in Patients with DCIS vs Invasive Breast Cancer in a Large, Integrated Health Care System"],"prefix":"10.1245","volume":"33","author":[{"given":"Jessica M.","family":"Dzubnar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurel A.","family":"Habel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Fang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Karlea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Hoodfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica C.","family":"Shim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"issue":"5","key":"19053_CR1","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1200\/JCO.23.02225","volume":"42","author":"I Bedrosian","year":"2024","unstructured":"Bedrosian I, Somerfield MR, Achatz MI, et al. Germline Testing in patients with breast cancer: ASCO-society of surgical oncology guideline. J Clin Oncol. 2024;42(5):584\u2013604.","journal-title":"J Clin Oncol."},{"key":"19053_CR2","unstructured":"Dwyer M. NCCN clinical practice guidelines in oncology (NCCN Guidelines \u00ae ) genetic\/familial high-risk assessment: breast, ovarian, and pancreatic. 2024. https:\/\/www.nccn.org. Accessed 1 Dec 2025."},{"issue":"10","key":"19053_CR3","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1245\/s10434-019-07549-8","volume":"26","author":"ER Manahan","year":"2019","unstructured":"Manahan ER, Kuerer HM, Sebastian M, et al. Consensus guidelines on genetic; testing for hereditary breast cancer from the American Society of Breast Surgeons. Ann Surg Oncol. 2019;26(10):3025\u201331.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"19053_CR4","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","volume":"7","author":"NJ Samadder","year":"2021","unstructured":"Samadder NJ, Riegert-Johnson D, Boardman L, et al. Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome. JAMA Oncol. 2021;7(2):230\u20137.","journal-title":"JAMA Oncol."},{"issue":"8","key":"19053_CR5","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/jmg-2022-108790","volume":"60","author":"DG Evans","year":"2023","unstructured":"Evans DG, Sithambaram S, van Veen EM, et al. Differential involvement of germline pathogenic variants in breast cancer genes between DCIS and low-grade invasive cancers. J Med Genet. 2023;60(8):740\u20136.","journal-title":"J Med Genet."},{"issue":"1","key":"19053_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1158\/1078-0432.CCR-24-1884","volume":"31","author":"H Huang","year":"2025","unstructured":"Huang H, Couch RE, Karam R, et al. Pathogenic variants in cancer susceptibility genes predispose to ductal carcinoma in situ of the breast. Clin Cancer Res. 2025;31(1):130\u20138.","journal-title":"Clin Cancer Res."},{"issue":"1","key":"19053_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13058-019-1143-y","volume":"21","author":"C Petridis","year":"2019","unstructured":"Petridis C, Arora I, Shah V, et al. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years. Breast Cancer Res. 2019;21(1):58.","journal-title":"Breast Cancer Res."},{"issue":"1","key":"19053_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.15430\/JCP.25.001","volume":"30","author":"M Zafar","year":"2025","unstructured":"Zafar M, Krishnakumar M, Reddy A. Impact of early testing and analysis of germline genetic mutation in patients with breast cancer: a single institution experience. J Cancer Prev. 2025;30(1):41\u20136. https:\/\/doi.org\/10.15430\/JCP.25.001.","journal-title":"J Cancer Prev."},{"issue":"10","key":"19053_CR9","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cncr.30498","volume":"123","author":"SS Buys","year":"2017","unstructured":"Buys SS, Sandbach JF, Gammon A, et al. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer. 2017;123(10):1721\u201330.","journal-title":"Cancer."},{"issue":"13","key":"19053_CR10","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","volume":"34","author":"N Tung","year":"2016","unstructured":"Tung N, Lin NU, Kidd J, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol. 2016;34(13):1460\u20138.","journal-title":"J Clin Oncol."},{"issue":"1","key":"19053_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1245\/s10434-024-16223-7","volume":"32","author":"V Shim","year":"2025","unstructured":"Shim V, Karlea A, Brenman LM, et al. Mainstream germline genetic testing with expanded eligibility for early breast cancer patients in a large integrated health system. Ann Surg Oncol. 2025;32(1):75\u201383.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"19053_CR12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1001\/jama.2016.16918","volume":"317","author":"AW Kurian","year":"2017","unstructured":"Kurian AW, Griffith KA, Hamilton AS, et al. Genetic testing and counseling among patients with newly diagnosed breast cancer. JAMA. 2017;317(5):531\u20134.","journal-title":"JAMA."},{"key":"19053_CR13","doi-asserted-by":"publisher","first-page":"918757","DOI":"10.3389\/fonc.2022.918757","volume":"12","author":"L Turza","year":"2022","unstructured":"Turza L, Lovejoy LA, Turner CE, Shriver CD, Ellsworth RE. Eligibility, uptake and response to germline genetic testing in women with DCIS. Front Oncol. 2022;12:918757.","journal-title":"Front Oncol."},{"issue":"8","key":"19053_CR14","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1002\/cncr.34126","volume":"128","author":"SM Rosenberg","year":"2022","unstructured":"Rosenberg SM, Gierisch JM, Revette AC, et al. \u201cIs it cancer or not?\u201d A qualitative exploration of survivor concerns surrounding the diagnosis and treatment of ductal carcinoma in situ. Cancer. 2022;128(8):1676\u201383.","journal-title":"Cancer."},{"issue":"10445","key":"19053_CR15","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1016\/S0140-6736(24)00425-2","volume":"403","author":"S Delaloge","year":"2024","unstructured":"Delaloge S, Khan SA, Wesseling J, Whelan T. Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment. Lancet. 2024;403(10445):2734\u201346.","journal-title":"Lancet."},{"issue":"11","key":"19053_CR16","doi-asserted-by":"publisher","first-page":"6454","DOI":"10.1245\/s10434-023-13745-4","volume":"30","author":"DS Hsu","year":"2023","unstructured":"Hsu DS, Jiang SF, Habel LA, et al. Germline genetic testing Among women <\/= 45 years of age with ductal carcinoma in situ versus invasive breast cancer in a large integrated health care system. Ann Surg Oncol. 2023;30(11):6454\u201361.","journal-title":"Ann Surg Oncol."},{"issue":"15","key":"19053_CR17","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1200\/JCO.18.01854","volume":"37","author":"AW Kurian","year":"2019","unstructured":"Kurian AW, Ward KC, Howlader N, et al. Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. J Clin Oncol. 2019;37(15):1305\u201315.","journal-title":"J Clin Oncol."},{"issue":"22","key":"19053_CR18","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1200\/JCO.2015.66.0019","volume":"34","author":"AM McCarthy","year":"2016","unstructured":"McCarthy AM, Bristol M, Domchek SM, et al. Health care segregation, physician recommendation, and racial disparities in BRCA1\/2 testing among women with breast cancer. J Clin Oncol. 2016;34(22):2610\u20138.","journal-title":"J Clin Oncol."},{"issue":"2","key":"19053_CR19","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1245\/s10434-022-12595-w","volume":"30","author":"JO Culver","year":"2023","unstructured":"Culver JO, Freiberg Y, Ricker C, et al. Integration of universal germline genetic testing for all new breast cancer patients. Ann Surg Oncol. 2023;30(2):1017\u201325.","journal-title":"Ann Surg Oncol."},{"key":"19053_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1200\/EDBK_238987","volume":"39","author":"S Yadav","year":"2019","unstructured":"Yadav S, Couch FJ. Germline genetic testing for breast cancer risk: the past, present, and future. Am Soc Clin Oncol Educ Book. 2019;39:61\u201374.","journal-title":"Am Soc Clin Oncol Educ Book."},{"issue":"4","key":"19053_CR21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1001\/jamaoncol.2021.6204","volume":"8","author":"KP Lowry","year":"2022","unstructured":"Lowry KP, Geuzinge HA, Stout NK, et al. Breast cancer screening Strategies for women With ATM, CHEK2, and PALB2 pathogenic variants: a comparative modeling analysis. JAMA Oncol. 2022;8(4):587\u201396.","journal-title":"JAMA Oncol."},{"issue":"11","key":"19053_CR22","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1001\/jama.2024.26698","volume":"333","author":"ES Hwang","year":"2025","unstructured":"Hwang ES, Hyslop T, Lynch T, et al. Active monitoring with or without endocrine therapy for low-risk ductal carcinoma in situ: the COMET randomized clinical trial. JAMA. 2025;333(11):972\u201380.","journal-title":"JAMA."},{"key":"19053_CR23","doi-asserted-by":"publisher","first-page":"113276","DOI":"10.1016\/j.ejca.2023.113276","volume":"192","author":"R Schmitz","year":"2023","unstructured":"Schmitz R, Engelhardt EG, Gerritsma MA, et al. Active surveillance versus treatment in low-risk DCIS: Women\u2019s preferences in the LORD-trial. Eur J Cancer. 2023;192:113276.","journal-title":"Eur J Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-19053-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-19053-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-19053-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:25:38Z","timestamp":1776255938000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-19053-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["19053"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-19053-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no commercial interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}